尋常性ざ瘡治療薬の世界市場:治験レビュー

◆英語タイトル:Acne Vulgaris Global Clinical Trials Review, H1, 2020
◆商品コード:GDT20FB0108
◆発行会社(リサーチ会社):GlobalData
◆発行日:2020年1月
◆ページ数:516
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Enterprisewide Price(複数事業所内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Acne Vulgaris Global Clinical Trials Review, H1, 2020
Summary

GlobalData’s clinical trial report, “Acne Vulgaris Global Clinical Trials Review, H1, 2020″ provides an overview of Acne Vulgaris Clinical trials scenario. This report provides top line data relating to the clinical trials on Acne Vulgaris. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalData’s proprietary database – Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

【レポートの目次】

Table of Contents
List of Tables
List of Figures
Report Guidance
GlobalData Clinical Trials Report Coverage
Clinical Trials by Region
Clinical Trials and Average Enrollment by Country
Top Five Countries Contributing to Clinical Trials in Asia-Pacific
Top Five Countries Contributing to Clinical Trials in Europe
Top Countries Contributing to Clinical Trials in North America
Top Five Countries Contributing to Clinical Trials in Middle East and Africa
Top Five Countries Contributing to Clinical Trials in Central and South America
Clinical Trials by G7 Countries: Proportion of Acne Vulgaris to Dermatology Clinical Trials
Clinical Trials by Phase in G7 Countries
Clinical Trials in G7 Countries by Trial Status
Clinical Trials by E7 Countries: Proportion of Acne Vulgaris to Dermatology Clinical Trials
Clinical Trials by Phase in E7 Countries
Clinical Trials in E7 Countries by Trial Status
Clinical Trials by Phase
In Progress Trials by Phase
Clinical Trials by Trial Status
Clinical Trials by End Point Status
Subjects Recruited Over a Period of Time
Clinical Trials by Sponsor Type
Prominent Sponsors
Top Companies Participating in Acne Vulgaris Therapeutics Clinical Trials
Prominent Drugs
Latest Clinical Trials News on Acne Vulgaris
Nov 18, 2019: Foamix announces enrollment completion of phase 2 acne clinical trial for FCD105 minocycline 3% and adapalene 0.3% combination foam
Nov 04, 2019: Foamix announces publication of AMZEEQ (minocycline) topical foam long term safety data for treatment up to 1 year in Journal of Clinical and Aesthetic Dermatology
Oct 22, 2019: Botanix announces BTX 1503 data and progression to Phase 3
Oct 18, 2019: Foamix receives FDA approval of AMZEEQ topical minocycline treatment for millions of moderate to severe acne sufferers
Oct 15, 2019: Bausch Health’s Ortho Dermatologics business to present data on tazarotene at The Fall Clinical Dermatology Conference
Clinical Trial Profile Snapshots
Appendix
Abbreviations
Definitions
Research Methodology
Secondary Research
About GlobalData
Contact Us
Source

List of Tables
Acne Vulgaris Therapeutics, Global, Clinical Trials by Region, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Europe, Top Five Countries, 2020*
Acne Vulgaris Therapeutics Clinical Trials, North America, Top Countries, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Central and South America, Top Five Countries, 2020*
Proportion of Acne Vulgaris to Dermatology Clinical Trials, G7 Countries (%), 2020*
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
Proportion of Acne Vulgaris to Dermatology Clinical Trials, E7 Countries (%), 2020*
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials by Phase, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Phase 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials by Trial Status, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, by End Point Status, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Acne Vulgaris Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*

List of Figures
Acne Vulgaris Therapeutics, Global, Clinical Trials by Region (%), 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2020*
Acne Vulgaris Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2020*
Acne Vulgaris Therapeutics Clinical Trials, North America, Top Countries (%), 2020*
Acne Vulgaris Therapeutics Clinical Trials, Middle East and Africa, Top Five Countries (%), 2020*
Acne Vulgaris Therapeutics Clinical Trials, Central and South America, Top Five Countries (%), 2020*
Proportion of Acne Vulgaris to Dermatology Clinical Trials, G7 Countries (%), 2020*
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Phase, 2020*
Acne Vulgaris Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2020*
Proportion of Acne Vulgaris to Dermatology Clinical Trials, E7 Countries (%), 2020*
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Phase, 2020*
Acne Vulgaris Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials by Phase (%), 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials In Progress by Phase, 2020*
Acne Vulgaris Therapeutics, Global, Clinical Trials by Trial Status, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, by End Point Status, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2014-2018
Acne Vulgaris Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Key Sponsors, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Top Companies by Phase, 2020*
Acne Vulgaris Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2020*
GlobalData Methodology

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[尋常性ざ瘡治療薬の世界市場:治験レビュー]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆